

Preliminary
Results of
using
Augmented
NAC
by Italian
oncologist

ZeroSpike

March, 30 2023



INTEGRATED THERAPIES

FIRST EXPERIENCE OF USING "AUGMENTED NAC"
INSTEAD OF STANDARD N-ACETYLCYSTEINE



N.PANTANO@LIBERO.IT

+393382712178



POLIAMBULATORIO.ORIONE@GMAIL.COM

+390916570591

[VIA GINO MARINUZZI, 98 PALERMO.](#)

Web: poliambulatorio-orione.com

ONCOLOGY HYPERTHERMIA:

EARLY CLINICAL RESULTS

- According to a study conducted by J. Van der Zee, hyperthermia used as a single modality shows an overall response of 13%.

When adjuvanted with radiotherapy, improvement of clinical condition is observed significant

- Improvements had been seen for rectal, bladder cancers, Lung, vulva and vagina, esophagus.
- In particular, improvements have been reported by combining hyperthermia with radiotherapy

Table 1. Summary of randomised trials showing significantly better results following a combination of radiotherapy (RT), chemotherapy (CT) or RT plus CT with hyperthermia (HT), compared with the same treatment without HT

Ref no.	Tumour	Treatment	Patients (lesions)	End point	Effect with HT	Effect without HT
[49, 50]	Lymphnodes of head and neck tumours	RT	41 [44]	CR rate	83%	41%
				5-year local control	69%	24%
				5-year survival	53%	0%
[51]	Melanoma	RT	70 (138)	CR rate	62%	35%
				2-year local control	46%	28%
[52]	Breast	RT	306	CR rate	59%	41%
[53]	Glioblastoma multiforme	Surgery, RT	68	Median survival	85 weeks	76 weeks
				2-year survival	31%	15%
[54]	Bladder, cervix and rectum	RT	298	CR rate	55%	39%
				3-year survival	30%	24%
[55]	Rectum	RT, surgery	115	5-year survival	36%	7%
[56]	Bladder	CT	52	pCR	66%	22%
[57]	Cervix	RT	64	CR	55%	31%
[58]	Various	RT	92	Response	82%	63%
[59]	Lung	CT	44	Response	68%	36%
[60]	Cervix	RT	40	CR	85%	50%
[61]	Rectum	RT	14	Response	100%	20%
[62]	Oesophagus	RT, CT	66	CR	25%	6%
[63]	Vulva/vagina	CT	65	Response	59%	19%
[64]	Bladder	RT, surgery	102	3-year survival	94%	67%
[65]	Oesophagus	RT, CT, surgery	53	Palliation	70%	8%
[66]	Oesophagus	RT	125	3-year survival	42%	24%
[67]	Rectum	RT, surgery	122	pCR	23%	5%

J. Van der Zee. Heating a patient: a promising approach? Annals of Oncology 13: 1173-1184.2002

COMPLEMENTARY REDUCING ANTIDEGENERATIVE PUCCIO (C.R.A.PU) PROTOCOL

- Perform once every 24 hours for 20 consecutive days intravenous infusion of 500 ml physiological saline to which is added:
 - ❖ No. 3 vials of **600 mg of GSH** - "Glutathione Germed" (for a total of 1800 mg)
 - ❖ No. 2 **300 mg** vials of **N-acetylcysteine** (for a total of 600 mg)
 - ❖ No. 1 **gr.** vials of **Vitamin C** (2 gr. in case of brain metastasis)
- Most relevant effects:
 - eliminates cachexia
 - Eliminates the cause in the body of oxidative stress
 - activates the immune system
- ✓ 1 cycle of C.R.A.Pu protocol = 20 drips
- ✓ 1 cycle of Hyperthermia protocol = 10 sessions

PATIENTS TREATED WITH AUGMENTED NAC INSTEAD OF STANDARD NAC (1/2)

HYPERTHERMIA PATIENT TABLE

IP	ANAMNESIS	OUTCOME	PRE VALUES TREATMENT	POST VALUES. TREATMENT	SIDE EFFECTS	OTHER THERAPIES.	PERIOD TREAT.
01\22	CARCINOMA OF MAMMELLA	OK	OUT RANGE*	WITHIN THE RANGE*	BEARABLE PAINS FROM NOT TAKE PAINKILLER	NO	2 MONTHS
02\22	CARCINOMA OF MAMMELLA	OK	OUT RANGE*	WITHIN THE RANGE*	NO	NO	IN PROGRESS
03\22	CARCINOMA OF THE MAMMELLA	OK	OUT RANGE*	WITHIN THE RANGE*	NO	NO	IN PROGRESS
04\22	CARCINOMA OF MAMMELLA	OK	OUT RANGE*	(PENDING. EXAMINATIONS)	NO	NO	IN PROGRESS
05\22	CARCINOMA POLMONARY	OK	OUT RANGE*	PARTLY BY THE RANGE*	NO	RADIOTHERAPY	IN PROGRESS
06\22	CARCINOMA POLMONARY	OK	OUT RANGE*	PARTLY BY THE RANGE*	RELIEF FROM PAIN	CHEMOTHERAPY	1 MONTH
08/22	CARCINOMA TO PROSTATE	OK	OUT RANGE*	WITHIN THE RANGE*	NO	HORMONOTHERAPY	2 MONTHS

** specific values can be found in the table on page 3-4*

N.B. Complete data can be found at Poliambulatorio Orione s.r.l. - Palermo

PATIENTS TABLE

Patient	ANAMNESIS	OUTCOME	PRE VALUES TREATMENT	POST VALUES. TREATMENT	SIDE EFFECTS	OTHER THERAPIES.	PERIOD TREAT.
Andrea	T.I.A.	OK	BY. RANGE*	WITHIN THE RANGE*	NO	NO	4 MONTHS
Happy	D12 stenosis	NO RESULT	BY. RANGE*	WITHIN THE RANGE*	NO	NO	IN PROGRESS

N.B. Complete data can be found at Poliambulatorio Orione s.r.l. - Palermo

RESULTS OBTAINED (1/2)

PATIENTS	LDH	Electrophoresis protein (albumin)	Transaminases G.O.T	Transaminases G.P.T	GGT	D-Dimer	Homocysteine	Ferritin
01/22 Pre-treatment values	180 IU/L	49,3 %	38 IU/L	26 IU/L	32 IU/L	2361 ng/ml	12.10 mmol/L	324.00 ng/ml
01/22 Post-treatment values	/	/	/	/	/	/	/	/
02/22 Pre-treatment values	157 IU/L	57,9 %	13 IU/L	19 IU/L	11 IU/L	221 ng/ml	11.80 mmol/L	30.88 ng/ml
02/22 Post-treatment values	164 IU/L	61,4 %	17 IU/L	14 IU/L	/	304 ng/ml	13.28 mmol/L	275 mg/ml
03/22 Pre-treatment values	110 IU/L	/	20 IU/L	10 IU/L	11 IU/L	/	/	/
03/22 Post-treatment values	174 IU/L	59,8 %	19 IU/L	11 IU/L	12 IU/L	446 ng/ml	/	237mg/dL
04/22 Pre-treatment values	385 IU/L	50,50 %	/	/	/	/	/	38.50 ng/ml
04/22 Post-treatment values	/	/	/	/	/	/	/	/

Complete data available at Poliambulatorio Orione s.r.l. - Palermo

RESULTS OBTAINED (2/2)

PATIENTS	LDH	Electrophoresis protein (albumin)	Transaminases G.O.T	Transaminases G.P.T	GGT	D-Dimer	Homocysteine	Ferritin
05/22 Pre-treatment values	200 U/L	51,2 %	18 U/L	20 U/L	19 U/L	630 mg/L	6.9 mg/dl	48 ng/ml
05/22 Post-treatment values	227 mU/mL	50 %	21 U/L	18 U/L	18 U/L	711 mg/L	15 mg/dl	55 ng/ml
06/22 Pre-treatment values	273 U/L	43,70%	/	/	33 IU/L	3.41 mg/L	13 mg/dl	358 ng/ml
06/22 Post-treatment values	775 U/L	36%	10 U/L	6 U/L	98 U/L	4634 ng/ml	11.3 mg/dl	474 ng/ml
08/22 Pre-treatment values	/	/	/	/	/	/	/	/
08/22 Post-treatment values	250 IU/L	/	19 IU/L	24 IU/L	19 IU/L	805 ng/ml	12.60 mmol/L	73.70 ng/ml

Complete data available at Poliambulatorio Orione s.r.l. - Palermo

ZeroSpike is a research project initiated by the non-profit civil society association Federazione Rinascimento Italia (FRI).

The results of our research are available to the international community of like-minded associations and doctors.

Just send us an e-mail: info@zerospike.org

For more information:

<https://zerospike.org/en/>

https://rinascimentoitalia.it/wp-content/uploads/2022/01/FRI_Presentation_2022_ENGLISH.pdf